Tocilizumab, an interleukin-6 (IL-6) receptor antagonist, demonstrated the strongest association with fungal pneumonia, specifically COVID-19-associated pulmonary aspergillosis (CAPA) and cryptococcosis (29, 30). The gene discussed is IL6; the disease is episodic ataxia type 2.